When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection - 19/08/20
Funding sources: This work was supported by the Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research to Dr King. Dr Damsky is supported by the Dermatology Foundation. |
|
Conflicts of interest: Dr Damsky has research funding from Pfizer, but it did not support this work, and is a consultant for Eli Lilly and Company. Dr King is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc, and is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, and Pfizer Inc, and is on speakers bureaus for Regeneron and Sanofi Genzyme. Dr Peterson has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 83 - N° 3
P. e269-e270 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.